nodes	percent_of_prediction	percent_of_DWPC	metapath
Varenicline—CHRNB2—prostate gland—urinary bladder cancer	0.00822	0.176	CbGeAlD
Varenicline—CHRNA3—prostate gland—urinary bladder cancer	0.00797	0.171	CbGeAlD
Varenicline—CHRNB2—smooth muscle tissue—urinary bladder cancer	0.00582	0.125	CbGeAlD
Varenicline—CHRNB2—urethra—urinary bladder cancer	0.0055	0.118	CbGeAlD
Varenicline—CHRNB2—vagina—urinary bladder cancer	0.00406	0.087	CbGeAlD
Varenicline—CHRNA7—renal system—urinary bladder cancer	0.00355	0.0761	CbGeAlD
Varenicline—CHRFAM7A—female reproductive system—urinary bladder cancer	0.00352	0.0754	CbGeAlD
Varenicline—CHRNA7—female reproductive system—urinary bladder cancer	0.00284	0.0609	CbGeAlD
Varenicline—CHRNB2—lymph node—urinary bladder cancer	0.00262	0.0563	CbGeAlD
Varenicline—CHRNA3—lymph node—urinary bladder cancer	0.00254	0.0546	CbGeAlD
Varenicline—Visual impairment—Methotrexate—urinary bladder cancer	0.000655	0.000687	CcSEcCtD
Varenicline—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.00065	0.000681	CcSEcCtD
Varenicline—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000648	0.00068	CcSEcCtD
Varenicline—Bradycardia—Epirubicin—urinary bladder cancer	0.000647	0.000679	CcSEcCtD
Varenicline—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000646	0.000677	CcSEcCtD
Varenicline—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000642	0.000674	CcSEcCtD
Varenicline—Urticaria—Etoposide—urinary bladder cancer	0.00064	0.000671	CcSEcCtD
Varenicline—Stomatitis—Doxorubicin—urinary bladder cancer	0.000639	0.00067	CcSEcCtD
Varenicline—Abdominal pain—Etoposide—urinary bladder cancer	0.000637	0.000668	CcSEcCtD
Varenicline—Body temperature increased—Etoposide—urinary bladder cancer	0.000637	0.000668	CcSEcCtD
Varenicline—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000637	0.000668	CcSEcCtD
Varenicline—Eye disorder—Methotrexate—urinary bladder cancer	0.000635	0.000666	CcSEcCtD
Varenicline—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000635	0.000666	CcSEcCtD
Varenicline—Tinnitus—Methotrexate—urinary bladder cancer	0.000633	0.000664	CcSEcCtD
Varenicline—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000633	0.000664	CcSEcCtD
Varenicline—Asthenia—Cisplatin—urinary bladder cancer	0.000631	0.000662	CcSEcCtD
Varenicline—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000631	0.000661	CcSEcCtD
Varenicline—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000628	0.000659	CcSEcCtD
Varenicline—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000626	0.000657	CcSEcCtD
Varenicline—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000625	0.000655	CcSEcCtD
Varenicline—Urethral disorder—Epirubicin—urinary bladder cancer	0.000623	0.000654	CcSEcCtD
Varenicline—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.00062	0.00065	CcSEcCtD
Varenicline—Epistaxis—Doxorubicin—urinary bladder cancer	0.000618	0.000648	CcSEcCtD
Varenicline—Angiopathy—Methotrexate—urinary bladder cancer	0.000616	0.000647	CcSEcCtD
Varenicline—Sinusitis—Doxorubicin—urinary bladder cancer	0.000615	0.000645	CcSEcCtD
Varenicline—Immune system disorder—Methotrexate—urinary bladder cancer	0.000614	0.000644	CcSEcCtD
Varenicline—Dizziness—Fluorouracil—urinary bladder cancer	0.000614	0.000644	CcSEcCtD
Varenicline—Visual impairment—Epirubicin—urinary bladder cancer	0.000613	0.000643	CcSEcCtD
Varenicline—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000612	0.000642	CcSEcCtD
Varenicline—Chills—Methotrexate—urinary bladder cancer	0.00061	0.000639	CcSEcCtD
Varenicline—Diarrhoea—Cisplatin—urinary bladder cancer	0.000602	0.000631	CcSEcCtD
Varenicline—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000601	0.000631	CcSEcCtD
Varenicline—Vomiting—Gemcitabine—urinary bladder cancer	0.0006	0.000629	CcSEcCtD
Varenicline—Bradycardia—Doxorubicin—urinary bladder cancer	0.000599	0.000628	CcSEcCtD
Varenicline—Mental disorder—Methotrexate—urinary bladder cancer	0.000595	0.000624	CcSEcCtD
Varenicline—Rash—Gemcitabine—urinary bladder cancer	0.000595	0.000624	CcSEcCtD
Varenicline—Dermatitis—Gemcitabine—urinary bladder cancer	0.000594	0.000624	CcSEcCtD
Varenicline—Eye disorder—Epirubicin—urinary bladder cancer	0.000594	0.000623	CcSEcCtD
Varenicline—Hypersensitivity—Etoposide—urinary bladder cancer	0.000594	0.000623	CcSEcCtD
Varenicline—Tinnitus—Epirubicin—urinary bladder cancer	0.000593	0.000622	CcSEcCtD
Varenicline—Malnutrition—Methotrexate—urinary bladder cancer	0.000591	0.00062	CcSEcCtD
Varenicline—Erythema—Methotrexate—urinary bladder cancer	0.000591	0.00062	CcSEcCtD
Varenicline—Headache—Gemcitabine—urinary bladder cancer	0.000591	0.00062	CcSEcCtD
Varenicline—Cardiac disorder—Epirubicin—urinary bladder cancer	0.00059	0.000619	CcSEcCtD
Varenicline—Vomiting—Fluorouracil—urinary bladder cancer	0.00059	0.000619	CcSEcCtD
Varenicline—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000585	0.000614	CcSEcCtD
Varenicline—Rash—Fluorouracil—urinary bladder cancer	0.000585	0.000614	CcSEcCtD
Varenicline—Dermatitis—Fluorouracil—urinary bladder cancer	0.000584	0.000613	CcSEcCtD
Varenicline—Headache—Fluorouracil—urinary bladder cancer	0.000581	0.00061	CcSEcCtD
Varenicline—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000581	0.000609	CcSEcCtD
Varenicline—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.00058	0.000608	CcSEcCtD
Varenicline—Dysgeusia—Methotrexate—urinary bladder cancer	0.000579	0.000607	CcSEcCtD
Varenicline—Asthenia—Etoposide—urinary bladder cancer	0.000578	0.000606	CcSEcCtD
Varenicline—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000578	0.000606	CcSEcCtD
Varenicline—Angiopathy—Epirubicin—urinary bladder cancer	0.000577	0.000605	CcSEcCtD
Varenicline—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000577	0.000605	CcSEcCtD
Varenicline—Immune system disorder—Epirubicin—urinary bladder cancer	0.000574	0.000602	CcSEcCtD
Varenicline—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000573	0.000601	CcSEcCtD
Varenicline—Back pain—Methotrexate—urinary bladder cancer	0.000572	0.0006	CcSEcCtD
Varenicline—Chills—Epirubicin—urinary bladder cancer	0.00057	0.000598	CcSEcCtD
Varenicline—Pruritus—Etoposide—urinary bladder cancer	0.00057	0.000598	CcSEcCtD
Varenicline—Arrhythmia—Epirubicin—urinary bladder cancer	0.000568	0.000596	CcSEcCtD
Varenicline—Visual impairment—Doxorubicin—urinary bladder cancer	0.000567	0.000595	CcSEcCtD
Varenicline—Nausea—Gemcitabine—urinary bladder cancer	0.000561	0.000588	CcSEcCtD
Varenicline—Vomiting—Cisplatin—urinary bladder cancer	0.000559	0.000587	CcSEcCtD
Varenicline—Vision blurred—Methotrexate—urinary bladder cancer	0.000557	0.000585	CcSEcCtD
Varenicline—Mental disorder—Epirubicin—urinary bladder cancer	0.000557	0.000584	CcSEcCtD
Varenicline—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000556	0.000583	CcSEcCtD
Varenicline—Rash—Cisplatin—urinary bladder cancer	0.000555	0.000582	CcSEcCtD
Varenicline—Dermatitis—Cisplatin—urinary bladder cancer	0.000554	0.000581	CcSEcCtD
Varenicline—Erythema—Epirubicin—urinary bladder cancer	0.000553	0.000581	CcSEcCtD
Varenicline—Malnutrition—Epirubicin—urinary bladder cancer	0.000553	0.000581	CcSEcCtD
Varenicline—Diarrhoea—Etoposide—urinary bladder cancer	0.000551	0.000578	CcSEcCtD
Varenicline—Nausea—Fluorouracil—urinary bladder cancer	0.000551	0.000578	CcSEcCtD
Varenicline—Eye disorder—Doxorubicin—urinary bladder cancer	0.00055	0.000577	CcSEcCtD
Varenicline—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000549	0.000576	CcSEcCtD
Varenicline—Tinnitus—Doxorubicin—urinary bladder cancer	0.000548	0.000575	CcSEcCtD
Varenicline—Anaemia—Methotrexate—urinary bladder cancer	0.000547	0.000573	CcSEcCtD
Varenicline—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000546	0.000573	CcSEcCtD
Varenicline—Flatulence—Epirubicin—urinary bladder cancer	0.000545	0.000572	CcSEcCtD
Varenicline—Dysgeusia—Epirubicin—urinary bladder cancer	0.000542	0.000568	CcSEcCtD
Varenicline—Back pain—Epirubicin—urinary bladder cancer	0.000535	0.000562	CcSEcCtD
Varenicline—Angiopathy—Doxorubicin—urinary bladder cancer	0.000534	0.00056	CcSEcCtD
Varenicline—Malaise—Methotrexate—urinary bladder cancer	0.000533	0.000559	CcSEcCtD
Varenicline—Dizziness—Etoposide—urinary bladder cancer	0.000533	0.000559	CcSEcCtD
Varenicline—Muscle spasms—Epirubicin—urinary bladder cancer	0.000532	0.000558	CcSEcCtD
Varenicline—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000531	0.000557	CcSEcCtD
Varenicline—Vertigo—Methotrexate—urinary bladder cancer	0.000531	0.000557	CcSEcCtD
Varenicline—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.00053	0.000556	CcSEcCtD
Varenicline—Chills—Doxorubicin—urinary bladder cancer	0.000528	0.000554	CcSEcCtD
Varenicline—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000526	0.000551	CcSEcCtD
Varenicline—Nausea—Cisplatin—urinary bladder cancer	0.000522	0.000548	CcSEcCtD
Varenicline—Vision blurred—Epirubicin—urinary bladder cancer	0.000522	0.000547	CcSEcCtD
Varenicline—Cough—Methotrexate—urinary bladder cancer	0.000516	0.000541	CcSEcCtD
Varenicline—Mental disorder—Doxorubicin—urinary bladder cancer	0.000515	0.000541	CcSEcCtD
Varenicline—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000514	0.000539	CcSEcCtD
Varenicline—Convulsion—Methotrexate—urinary bladder cancer	0.000512	0.000537	CcSEcCtD
Varenicline—Vomiting—Etoposide—urinary bladder cancer	0.000512	0.000537	CcSEcCtD
Varenicline—Erythema—Doxorubicin—urinary bladder cancer	0.000512	0.000537	CcSEcCtD
Varenicline—Malnutrition—Doxorubicin—urinary bladder cancer	0.000512	0.000537	CcSEcCtD
Varenicline—Anaemia—Epirubicin—urinary bladder cancer	0.000512	0.000537	CcSEcCtD
Varenicline—Agitation—Epirubicin—urinary bladder cancer	0.000509	0.000533	CcSEcCtD
Varenicline—Rash—Etoposide—urinary bladder cancer	0.000508	0.000533	CcSEcCtD
Varenicline—Dermatitis—Etoposide—urinary bladder cancer	0.000508	0.000532	CcSEcCtD
Varenicline—Headache—Etoposide—urinary bladder cancer	0.000505	0.000529	CcSEcCtD
Varenicline—Flatulence—Doxorubicin—urinary bladder cancer	0.000505	0.000529	CcSEcCtD
Varenicline—Chest pain—Methotrexate—urinary bladder cancer	0.000503	0.000528	CcSEcCtD
Varenicline—Myalgia—Methotrexate—urinary bladder cancer	0.000503	0.000528	CcSEcCtD
Varenicline—Arthralgia—Methotrexate—urinary bladder cancer	0.000503	0.000528	CcSEcCtD
Varenicline—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000501	0.000526	CcSEcCtD
Varenicline—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.0005	0.000524	CcSEcCtD
Varenicline—Malaise—Epirubicin—urinary bladder cancer	0.000499	0.000524	CcSEcCtD
Varenicline—Discomfort—Methotrexate—urinary bladder cancer	0.000497	0.000522	CcSEcCtD
Varenicline—Vertigo—Epirubicin—urinary bladder cancer	0.000497	0.000522	CcSEcCtD
Varenicline—Syncope—Epirubicin—urinary bladder cancer	0.000496	0.000521	CcSEcCtD
Varenicline—Back pain—Doxorubicin—urinary bladder cancer	0.000495	0.00052	CcSEcCtD
Varenicline—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000492	0.000516	CcSEcCtD
Varenicline—Palpitations—Epirubicin—urinary bladder cancer	0.000489	0.000513	CcSEcCtD
Varenicline—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000486	0.00051	CcSEcCtD
Varenicline—Cough—Epirubicin—urinary bladder cancer	0.000483	0.000507	CcSEcCtD
Varenicline—Vision blurred—Doxorubicin—urinary bladder cancer	0.000483	0.000506	CcSEcCtD
Varenicline—Convulsion—Epirubicin—urinary bladder cancer	0.00048	0.000503	CcSEcCtD
Varenicline—Infection—Methotrexate—urinary bladder cancer	0.00048	0.000503	CcSEcCtD
Varenicline—Nausea—Etoposide—urinary bladder cancer	0.000479	0.000502	CcSEcCtD
Varenicline—Hypertension—Epirubicin—urinary bladder cancer	0.000478	0.000501	CcSEcCtD
Varenicline—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000475	0.000498	CcSEcCtD
Varenicline—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000473	0.000496	CcSEcCtD
Varenicline—Anaemia—Doxorubicin—urinary bladder cancer	0.000473	0.000496	CcSEcCtD
Varenicline—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000473	0.000496	CcSEcCtD
Varenicline—Myalgia—Epirubicin—urinary bladder cancer	0.000471	0.000494	CcSEcCtD
Varenicline—Chest pain—Epirubicin—urinary bladder cancer	0.000471	0.000494	CcSEcCtD
Varenicline—Arthralgia—Epirubicin—urinary bladder cancer	0.000471	0.000494	CcSEcCtD
Varenicline—Agitation—Doxorubicin—urinary bladder cancer	0.000471	0.000494	CcSEcCtD
Varenicline—Anxiety—Epirubicin—urinary bladder cancer	0.00047	0.000493	CcSEcCtD
Varenicline—Skin disorder—Methotrexate—urinary bladder cancer	0.000469	0.000492	CcSEcCtD
Varenicline—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000468	0.000491	CcSEcCtD
Varenicline—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000467	0.000489	CcSEcCtD
Varenicline—Discomfort—Epirubicin—urinary bladder cancer	0.000466	0.000488	CcSEcCtD
Varenicline—Malaise—Doxorubicin—urinary bladder cancer	0.000462	0.000484	CcSEcCtD
Varenicline—Dry mouth—Epirubicin—urinary bladder cancer	0.000461	0.000483	CcSEcCtD
Varenicline—Vertigo—Doxorubicin—urinary bladder cancer	0.00046	0.000483	CcSEcCtD
Varenicline—Anorexia—Methotrexate—urinary bladder cancer	0.00046	0.000483	CcSEcCtD
Varenicline—Syncope—Doxorubicin—urinary bladder cancer	0.000459	0.000482	CcSEcCtD
Varenicline—Palpitations—Doxorubicin—urinary bladder cancer	0.000453	0.000475	CcSEcCtD
Varenicline—Oedema—Epirubicin—urinary bladder cancer	0.000452	0.000474	CcSEcCtD
Varenicline—Hypotension—Methotrexate—urinary bladder cancer	0.000451	0.000473	CcSEcCtD
Varenicline—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.00045	0.000472	CcSEcCtD
Varenicline—Infection—Epirubicin—urinary bladder cancer	0.000449	0.000471	CcSEcCtD
Varenicline—Cough—Doxorubicin—urinary bladder cancer	0.000447	0.000469	CcSEcCtD
Varenicline—Shock—Epirubicin—urinary bladder cancer	0.000444	0.000466	CcSEcCtD
Varenicline—Convulsion—Doxorubicin—urinary bladder cancer	0.000444	0.000465	CcSEcCtD
Varenicline—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000443	0.000465	CcSEcCtD
Varenicline—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000442	0.000464	CcSEcCtD
Varenicline—Hypertension—Doxorubicin—urinary bladder cancer	0.000442	0.000464	CcSEcCtD
Varenicline—Tachycardia—Epirubicin—urinary bladder cancer	0.000441	0.000462	CcSEcCtD
Varenicline—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.00044	0.000461	CcSEcCtD
Varenicline—Skin disorder—Epirubicin—urinary bladder cancer	0.000439	0.00046	CcSEcCtD
Varenicline—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000437	0.000458	CcSEcCtD
Varenicline—Insomnia—Methotrexate—urinary bladder cancer	0.000437	0.000458	CcSEcCtD
Varenicline—Chest pain—Doxorubicin—urinary bladder cancer	0.000436	0.000457	CcSEcCtD
Varenicline—Myalgia—Doxorubicin—urinary bladder cancer	0.000436	0.000457	CcSEcCtD
Varenicline—Arthralgia—Doxorubicin—urinary bladder cancer	0.000436	0.000457	CcSEcCtD
Varenicline—Anxiety—Doxorubicin—urinary bladder cancer	0.000434	0.000456	CcSEcCtD
Varenicline—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000433	0.000454	CcSEcCtD
Varenicline—Discomfort—Doxorubicin—urinary bladder cancer	0.000431	0.000452	CcSEcCtD
Varenicline—Anorexia—Epirubicin—urinary bladder cancer	0.000431	0.000452	CcSEcCtD
Varenicline—Dyspnoea—Methotrexate—urinary bladder cancer	0.00043	0.000451	CcSEcCtD
Varenicline—Somnolence—Methotrexate—urinary bladder cancer	0.000429	0.00045	CcSEcCtD
Varenicline—Dry mouth—Doxorubicin—urinary bladder cancer	0.000426	0.000447	CcSEcCtD
Varenicline—Dyspepsia—Methotrexate—urinary bladder cancer	0.000425	0.000446	CcSEcCtD
Varenicline—Hypotension—Epirubicin—urinary bladder cancer	0.000422	0.000443	CcSEcCtD
Varenicline—Decreased appetite—Methotrexate—urinary bladder cancer	0.00042	0.00044	CcSEcCtD
Varenicline—Oedema—Doxorubicin—urinary bladder cancer	0.000418	0.000438	CcSEcCtD
Varenicline—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000417	0.000437	CcSEcCtD
Varenicline—Fatigue—Methotrexate—urinary bladder cancer	0.000416	0.000436	CcSEcCtD
Varenicline—Infection—Doxorubicin—urinary bladder cancer	0.000415	0.000436	CcSEcCtD
Varenicline—Pain—Methotrexate—urinary bladder cancer	0.000413	0.000433	CcSEcCtD
Varenicline—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000412	0.000432	CcSEcCtD
Varenicline—Shock—Doxorubicin—urinary bladder cancer	0.000411	0.000431	CcSEcCtD
Varenicline—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.00041	0.00043	CcSEcCtD
Varenicline—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000409	0.000429	CcSEcCtD
Varenicline—Insomnia—Epirubicin—urinary bladder cancer	0.000409	0.000429	CcSEcCtD
Varenicline—Tachycardia—Doxorubicin—urinary bladder cancer	0.000408	0.000428	CcSEcCtD
Varenicline—Skin disorder—Doxorubicin—urinary bladder cancer	0.000406	0.000426	CcSEcCtD
Varenicline—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000404	0.000424	CcSEcCtD
Varenicline—Dyspnoea—Epirubicin—urinary bladder cancer	0.000403	0.000422	CcSEcCtD
Varenicline—Somnolence—Epirubicin—urinary bladder cancer	0.000402	0.000421	CcSEcCtD
Varenicline—Anorexia—Doxorubicin—urinary bladder cancer	0.000398	0.000418	CcSEcCtD
Varenicline—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000398	0.000417	CcSEcCtD
Varenicline—Dyspepsia—Epirubicin—urinary bladder cancer	0.000398	0.000417	CcSEcCtD
Varenicline—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000395	0.000414	CcSEcCtD
Varenicline—Decreased appetite—Epirubicin—urinary bladder cancer	0.000393	0.000412	CcSEcCtD
Varenicline—Hypotension—Doxorubicin—urinary bladder cancer	0.000391	0.00041	CcSEcCtD
Varenicline—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.00039	0.000409	CcSEcCtD
Varenicline—Fatigue—Epirubicin—urinary bladder cancer	0.000389	0.000408	CcSEcCtD
Varenicline—Pain—Epirubicin—urinary bladder cancer	0.000386	0.000405	CcSEcCtD
Varenicline—Constipation—Epirubicin—urinary bladder cancer	0.000386	0.000405	CcSEcCtD
Varenicline—Urticaria—Methotrexate—urinary bladder cancer	0.000383	0.000402	CcSEcCtD
Varenicline—Body temperature increased—Methotrexate—urinary bladder cancer	0.000382	0.0004	CcSEcCtD
Varenicline—Abdominal pain—Methotrexate—urinary bladder cancer	0.000382	0.0004	CcSEcCtD
Varenicline—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000381	0.000399	CcSEcCtD
Varenicline—Insomnia—Doxorubicin—urinary bladder cancer	0.000378	0.000396	CcSEcCtD
Varenicline—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000373	0.000391	CcSEcCtD
Varenicline—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000372	0.00039	CcSEcCtD
Varenicline—Somnolence—Doxorubicin—urinary bladder cancer	0.000372	0.00039	CcSEcCtD
Varenicline—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000369	0.000387	CcSEcCtD
Varenicline—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000368	0.000386	CcSEcCtD
Varenicline—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000363	0.000381	CcSEcCtD
Varenicline—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000361	0.000378	CcSEcCtD
Varenicline—Fatigue—Doxorubicin—urinary bladder cancer	0.00036	0.000378	CcSEcCtD
Varenicline—Urticaria—Epirubicin—urinary bladder cancer	0.000359	0.000376	CcSEcCtD
Varenicline—Constipation—Doxorubicin—urinary bladder cancer	0.000357	0.000375	CcSEcCtD
Varenicline—Pain—Doxorubicin—urinary bladder cancer	0.000357	0.000375	CcSEcCtD
Varenicline—Body temperature increased—Epirubicin—urinary bladder cancer	0.000357	0.000375	CcSEcCtD
Varenicline—Abdominal pain—Epirubicin—urinary bladder cancer	0.000357	0.000375	CcSEcCtD
Varenicline—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000356	0.000373	CcSEcCtD
Varenicline—Asthenia—Methotrexate—urinary bladder cancer	0.000346	0.000363	CcSEcCtD
Varenicline—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000344	0.000361	CcSEcCtD
Varenicline—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000342	0.000358	CcSEcCtD
Varenicline—Pruritus—Methotrexate—urinary bladder cancer	0.000341	0.000358	CcSEcCtD
Varenicline—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000333	0.000349	CcSEcCtD
Varenicline—Urticaria—Doxorubicin—urinary bladder cancer	0.000332	0.000348	CcSEcCtD
Varenicline—Abdominal pain—Doxorubicin—urinary bladder cancer	0.00033	0.000347	CcSEcCtD
Varenicline—Body temperature increased—Doxorubicin—urinary bladder cancer	0.00033	0.000347	CcSEcCtD
Varenicline—Diarrhoea—Methotrexate—urinary bladder cancer	0.00033	0.000346	CcSEcCtD
Varenicline—Asthenia—Epirubicin—urinary bladder cancer	0.000324	0.00034	CcSEcCtD
Varenicline—Pruritus—Epirubicin—urinary bladder cancer	0.00032	0.000335	CcSEcCtD
Varenicline—Dizziness—Methotrexate—urinary bladder cancer	0.000319	0.000335	CcSEcCtD
Varenicline—Diarrhoea—Epirubicin—urinary bladder cancer	0.000309	0.000324	CcSEcCtD
Varenicline—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000308	0.000323	CcSEcCtD
Varenicline—Vomiting—Methotrexate—urinary bladder cancer	0.000307	0.000322	CcSEcCtD
Varenicline—Rash—Methotrexate—urinary bladder cancer	0.000304	0.000319	CcSEcCtD
Varenicline—Dermatitis—Methotrexate—urinary bladder cancer	0.000304	0.000319	CcSEcCtD
Varenicline—Headache—Methotrexate—urinary bladder cancer	0.000302	0.000317	CcSEcCtD
Varenicline—Asthenia—Doxorubicin—urinary bladder cancer	0.0003	0.000315	CcSEcCtD
Varenicline—Dizziness—Epirubicin—urinary bladder cancer	0.000299	0.000313	CcSEcCtD
Varenicline—Pruritus—Doxorubicin—urinary bladder cancer	0.000296	0.00031	CcSEcCtD
Varenicline—Vomiting—Epirubicin—urinary bladder cancer	0.000287	0.000301	CcSEcCtD
Varenicline—Nausea—Methotrexate—urinary bladder cancer	0.000287	0.000301	CcSEcCtD
Varenicline—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000286	0.0003	CcSEcCtD
Varenicline—Rash—Epirubicin—urinary bladder cancer	0.000285	0.000299	CcSEcCtD
Varenicline—Dermatitis—Epirubicin—urinary bladder cancer	0.000285	0.000298	CcSEcCtD
Varenicline—Headache—Epirubicin—urinary bladder cancer	0.000283	0.000297	CcSEcCtD
Varenicline—Dizziness—Doxorubicin—urinary bladder cancer	0.000276	0.00029	CcSEcCtD
Varenicline—Nausea—Epirubicin—urinary bladder cancer	0.000268	0.000281	CcSEcCtD
Varenicline—Vomiting—Doxorubicin—urinary bladder cancer	0.000266	0.000279	CcSEcCtD
Varenicline—Rash—Doxorubicin—urinary bladder cancer	0.000264	0.000276	CcSEcCtD
Varenicline—Dermatitis—Doxorubicin—urinary bladder cancer	0.000263	0.000276	CcSEcCtD
Varenicline—Headache—Doxorubicin—urinary bladder cancer	0.000262	0.000275	CcSEcCtD
Varenicline—Nausea—Doxorubicin—urinary bladder cancer	0.000248	0.00026	CcSEcCtD
